Stockreport

Dyadic Reports 2023 Full Year Results and Recent Company Progress [Yahoo! Finance]

Dyadic International, Inc.  (DYAI) 
NASDAQ:AMEX Investor Relations: dyadic.com
PDF Reported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein receptor binding [Read more]